Tracking Rare Disease Patient Data Across Payer Transitions: Why Closed Claims Matter

Rare disease patient data and the hidden impact of payer transitions

In rare disease, payer transitions are not the exception. They are the norm, which makes maintaining complete, longitudinal rare disease patient data far more challenging and far more important than many teams realize.

About 70% of rare diseases begin in childhood, with many patients entering the healthcare system through Medicaid or Children’s Health Insurance Program (CHIP) before transitioning across coverage types throughout their lives.

When a real-world data source only captures patients within a single payer type, or loses visibility when coverage changes, the patient journey becomes fragmented.

For health economics and outcomes research (HEOR) and real-world evidence (RWE) teams building external control arms or natural history studies, already-small rare disease cohorts become even smaller. For commercial and patient-finding teams, it means missing patients, providers, and institutions that remain active but fall outside a single payer dataset.

Maintaining longitudinal rare disease patient data across Medicaid, commercial, and Medicare coverage can strengthen research quality, patient identification, provider mapping, and market visibility. As payer transitions become more common throughout a patient’s lifetime, continuity becomes just as important as scale.

What we’ll cover:

• Why rare disease patients transition between payer types more frequently than most populations
• The most common payer pathways in rare disease
• How payer changes fragment longitudinal patient data and create blind spots
• The impact of fragmented data on HEOR, RWE, patient-finding, and commercial strategies
• How linked closed claims data helps preserve continuity across coverage transitions

Why rare disease populations are different

Several characteristics make rare disease cohorts especially exposed to payer transitions:

• Pediatric onset. Roughly 70% of rare diseases manifest in childhood. Many of these patients enter through Medicaid or CHIP. Children make up close to half of all Medicaid enrollees.
• Disability pathways. Progressive conditions and hemophilia complications can qualify patients for Medicare before age 65 through Social Security Disability Insurance (SSDI), often alongside Medicaid.
• Treatment economics. Rare disease therapies routinely cost six or seven figures annually. Medicaid spending on rare-disease gene and RNA therapies grew from roughly $148M to $880M between 2017 and 2022, concentrating many patients within Medicaid.
• Eligibility churn. Coverage is not always continuous. Medicaid enrollment changes due to eligibility reviews, reenrollment, and coverage gaps create additional transitions that can interrupt longitudinal patient visibility.

The takeaway

A rare disease patient’s treatment journey is more likely to span multiple payer types than a typical commercially-insured patient’s treatment journey.

Studies and patient-finding analyses that draw from a single payer type, or even a single commercial data source, start at a representational disadvantage that compounds over time.

What payer transitions actually look like

Rare disease patients move through several common coverage pathways, many of which can create gaps in longitudinal patient data.

Pediatric Medicaid or CHIP to adult coverage

Patients diagnosed in childhood often transition from Medicaid or CHIP into commercial coverage, Marketplace plans, or adult Medicaid.

CHIP adds another layer of complexity. In many states, CHIP is administered through the same managed care organizations that support Medicaid and commercial plans. As a result, what appears to be a commercial-to-government transition in claims data may simply reflect a change in how coverage is reported. Without patient-level linkage, a single patient can appear as multiple unrelated records.

Commercial to Medicaid

As disease severity affects employment and caregiving responsibilities, families often move toward Medicaid. These transitions rarely occur in a straight line. Marketplace coverage, COBRA, and temporary gaps frequently sit between employer-sponsored coverage and Medicaid eligibility.

Commercial to Medicare under age 65

This pathway is especially common in rare disease populations.

Patients may qualify for SSDI, receive disability benefits, and ultimately transition into Medicare. Many also retain Medicaid as a secondary payer.

From a data perspective, the same patient may appear in commercial coverage, disappear during the transition period, and later reappear as a Medicare Advantage member under a different carrier. Without longitudinal continuity, that journey can look like multiple disconnected patients.

Commercial or Medicaid to Medicare at 65

The standard transition, but for later-diagnosed conditions like wild-type ATTR cardiomyopathy, this transition can fall close to the moment of diagnosis and treatment initiation. A study that observes patients only up to age 65 misses the treatment journey entirely.

Every payer transition creates a potential break in the record. In rare disease, where patient populations are already small, even modest attrition can have an outsized impact.

How fragmented rare disease patient data impacts research

For HEOR and RWE teams, payer transitions can directly affect study design and study quality.

• Natural history studies require years of continuous observation. Payer changes can shorten observation windows or split one patient into multiple records.
• External control arms depend on continuous visibility across the treatment journey. Patients lost during transitions may no longer qualify for inclusion.
• Treatment persistence and adherence studies require uninterrupted visibility into therapies and fills. Missing data can be mistaken for nonadherence.
• Diagnostic odyssey research often spans four to six years or more. Few patients remain with a single payer for that long.
• Burden-of-illness studies require stable observation periods before and after diagnosis.

How fragmented rare disease patient data impacts commercial strategy

The same discontinuities that challenge researchers also challenge commercial teams.

Patient-finding analyses undercount eligible patients. Patients who move from commercial coverage to Medicare, or from Medicaid to commercial coverage, disappear from single-payer datasets even though they continue receiving care.

As patients change coverage, they often change providers as well. That means provider mapping becomes incomplete, particularly during transitions from pediatric to adult care or between commercial and Medicare Advantage networks. When patients disappear, so do the physicians treating them.

Additionally, account-based planning can understate institutional volume. Commercial-only datasets may underrepresent health systems and academic medical centers that care for large Medicaid and dual-eligible rare disease populations.

The same challenge extends to diagnostic odyssey mapping. Referral patterns often span multiple payer types. Without longitudinal continuity, the journey is split into disconnected pieces, obscuring the path to diagnosis.
Finally, regional analyses can miss important pockets of concentration. Areas with high Medicaid enrollment, including rural communities and urban safety-net markets, can be underrepresented, creating an incomplete picture of where patients receive care.

All of these challenges create risk of missing patients, providers, institutions, and referral patterns that commercial teams don’t realize are absent.

When rare disease patient data becomes fragmented, market understanding becomes fragmented as well.

How linked closed claims preserves continuity

Inovalon’s closed claims data is sourced directly from health plans and pharmacy benefit managers across Medicaid, Medicare Advantage, and commercial coverage.

Because patients are linked across payer types, someone who transitions from Medicaid to commercial coverage, or from commercial coverage to Medicare Advantage, remains visible throughout their journey instead of appearing as a new record each time coverage changes.

That continuity is built into how the data is sourced and linked, not applied later as an analytical adjustment.

In rare disease, where patient populations are often small, every lost patient matters.

For use cases requiring broader provider and geographic visibility, open claims can complement closed claims with wider cross-payer reach for patient finding, prevalence estimation, and treatment pattern analyses.

Cross-payer continuity is especially important for:

• DMD and BMD long-term outcomes following Elevidys and other gene therapies
• SMA treatment persistence and switching across Spinraza, Zolgensma, and Evrysdi
• ATTR patient finding and diagnostic delay research
• Hemophilia A and B treatment patterns and provider mapping
• External control arm development for rare disease single-arm trials requiring regulatory or HTA defensibility
• Center-of-excellence identification and account-based planning for high-volume institutions treating patients across payer types

Why continuity matters

In rare disease, payer transitions are inevitable, but the risk of losing visibility is high. Every transition creates incomplete patient journeys, smaller research cohorts, and missed commercial opportunities.

Maintaining continuity in rare disease patient data helps researchers and commercial teams follow patients across Medicaid, commercial, and Medicare coverage, ensuring a more complete view of care over time.

Want to dive deeper?

Explore our white paper to learn how longitudinal patient visibility across payer types can strengthen rare disease research and commercial decision-making.

Frequently asked questions

Why are rare disease patients more likely to change payers than other populations?

Three factors stack: most rare diseases begin in childhood (driving Medicaid and CHIP enrollment), severe progressive conditions trigger disability pathways into Medicare under age 65, and high treatment costs concentrate patient populations within Medicaid and Medicare Advantage. The result is that rare disease patients spend more of their healthcare journey transitioning between payer types than a typical commercially-insured patient.

How does CHIP show up in real-world claims data?

CHIP is government-funded, but in most states it is delivered through private managed care organizations — frequently the same carrier brands that administer Medicaid and commercial coverage. That means a child on a separate CHIP program may appear in claims data under a commercial-style carrier name. Without patient-level linkage across coverage types, a later transition from CHIP into Medicaid can look like a commercial-to-government switch in the data even when the underlying coverage source hasn’t changed.

How do rare disease patients qualify for Medicare before age 65?

Through Social Security Disability Insurance (SSDI). After SSDI approval and a 24-month qualifying period — about 29 months from disability onset — patients are automatically enrolled in Medicare. ALS and end-stage renal disease are exceptions that waive the waiting period. Many progressive rare diseases meet SSDI criteria, making this an unusually common pathway in rare disease populations compared to the general under-65 population.

What’s the difference between closed claims and open claims for rare disease work?

Closed claims are sourced directly from health plans and pharmacy benefit managers and are linked at the patient level across Medicaid, Medicare Advantage, and commercial payer types, supporting longitudinal continuity across transitions. Open claims have a broader cross-payer footprint useful for prescriber mapping, patient finding at scale, and prevalence estimation. They are separate Inovalon assets with separate methodologies and different study and commercial applications — not interchangeable, not combined.

How does payer-transition continuity affect commercial teams, not just researchers?

Patient-finding analyses, prescriber footprint mapping, account-based commercial planning, and regional market sizing all depend on staying with the patient as their coverage changes. A data source that loses the patient through a transition also loses visibility into the next provider treating them, understates the institutions serving cross-payer populations, and biases geographic concentration estimates toward commercially insured regions.

---

Inovalon and design® and Inovalon® are trademarks of Inovalon, Inc.